Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$41.4B
282M shares
52-week range
$108.35 – $163.75
69% from low
Sector
LABORATORY ANALYTICAL INSTRUMENTS
Exchange
NYSE
CS
P/S (TTM)
5.6
EV / FCF (TTM)
30.5
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and diagnostics, cross lab operations consisting of consumables and services, and applied end markets. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations.
www.agilent.comNo one on the platform currently holds A.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 300,300 | $34.2M |
| Bridgewater Associatesas of 2026-03-31 | 73,689 | $8.4M |
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-06-30 | $0.2550 | 2026-07-22 |
| 2026-03-31 | $0.2550 | 2026-04-22 |
| 2026-01-06 | $0.2550 | 2026-01-28 |
| 2025-09-30 | $0.2480 | 2025-10-22 |
| 2025-07-01 | $0.2480 | 2025-07-23 |
| 2025-04-01 | $0.2480 | 2025-04-23 |
| 2024-12-31 | $0.2480 | 2025-01-22 |
| 2024-10-01 | $0.2360 | 2024-10-23 |
| 2024-07-02 | $0.2360 | 2024-07-24 |
| 2024-04-01 | $0.2360 | 2024-04-24 |
No one on the platform has traded A yet.
| 2023-12-29 | $0.2360 | 2024-01-24 |
| 2023-10-02 | $0.2250 | 2023-10-25 |
| Execution date | Ratio |
|---|---|
| 2014-11-03 | 1398-for-1000 |
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 16.2% | 17.4% | 15.6% | — | — | — |
| Rev. Growth % | 6.7% | 5.4% | ||||
| Profit Margin % | 18.8% | 18.8% | 16.1% | |||
| Free Cash Flow Margin % | 16.6% | 18.9% | 17.6% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is +3.3% on the P/E track.
At today's price, your expected annual return is +8.3% on the P/E track.
At today's price, your expected annual return is +12.4% on the P/E track.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $7.5B | +8.4% | $6.20 | $6.06–$6.22 | 23.7× | 12 |
| 2027 | $8.0B | +6.5% | $6.74 | $6.55–$7.00 | 21.8× | 13 |
| 2028 | $8.5B | +6.5% | $7.47 | $6.94–$8.03 | 19.6× | 7 |
| 2029 | $9.1B | +6.8% | $8.26 | $8.16–$8.36 | 17.8× | 3 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 7 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-26 | $1.49 | $1.62 | +8.7% |
| 2026-05-27 | $1.41 | $1.49 | +5.7% |
| 2026-02-25 | $1.37 | $1.36 | -0.7% |
| 2025-11-24 | $1.58 | $1.59 | +0.4% |
| 2025-08-27 | $1.37 | $1.37 | +0.0% |
| 2025-05-28 | $1.26 | $1.31 | +4.0% |
| 2025-02-26 | $1.28 | $1.31 | +2.3% |
| 2024-11-25 | $1.41 |
| $1.46 |
| +3.5% |
| $49.2B |
| — |
| HLNHaleon plc | $9.39 | +2.18% | $41.4B | — |
| INSMInsmed Incorporated | $125.30 | -3.18% | $27.2B | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$A REPLY: A Face Only A Mother Could Love by Robert Gaudette Wins the Reply AI Film Festival 2026, the International Competition Exploring the Intersection of Cinema and Artificial Intelligence https://marketwirenews.com/stock/a/news/reply-a-face-only-a-mother-could-love-by-robert-gaud-6139684371297912.html?utm_source=stocktwits
View on StockTwits ↗
Fundamental analysis of $A (AGILENT TECHNOLOGIES, INC.) based on financial data and reported results. #A #AGILENT
View on StockTwits ↗
$A Agilent Expands Digital Pathology Offering with U.S. Launch of the Agilent S540MD Slide Scanner System https://marketwirenews.com/stock/a/news/agilent-expands-digital-pathology-offering-with-u-s--6479782360281909.html?utm_source=stocktwits
View on StockTwits ↗
Wall St is expecting 1.73 EPS for $A Q4 [Reporting 11/30 AMC] http://www.estimize.com/intro/a?chart=historical&metric_name=eps&utm_content=
View on StockTwits ↗
There’s already an example inside NervGen’s own strategy: the company says it intends to use the RESTORE regulatory alignment and endpoint framework to inform future registrational-quality development in subacute tetraplegia. This creates enormous option value in an acquisition price. After successful RESTORE an acquirer thought: SCI = $X MS opportunity = $Y × probability of success Stroke = $Z × probability Hearing = $A × probability Peripheral nerve = $B × probability Other neurological indications = additional option value The buyer doesn’t need to believe every indication succeeds. If even one or two additional large indications work, the lifetime economics could dwarf SCI alone. That’s why Big Pharma often pays for risk-adjusted future optionality, rather than simply applying a multiple to the first indication’s expected sales.
View on StockTwits ↗
$A printed a new 52-week high today
View on StockTwits ↗
$A look at the monthly chart. Crazy set-up if it breaks out of the range
View on StockTwits ↗
$A (+2.1% pre) Agilent shares rise as strong Q3 results and improving demand support guidance upgrade https://ooc.bz/l/112464
View on StockTwits ↗
Stocks making the biggest moves after hours: Nvidia, Salesforce, CrowdStrike, Urban Outfitters and more $a $ihi Agilent Technologies — The medical technology stock jumped 4% on a stronger-than-expected revenue report for its third quarter. Agilent said it brought in $1.88 billion in revenue, while analysts polled by FactSet forecast $1.84 billion, per FactSet. https://www.cnbc.com/2026/08/26/stocks-making-the-biggest-moves-after-hours-nvda-crm-crwd-urbn-and-more.html?__source=iosappshare%7Ccom.stocktwits.StockTwits.STShareExtension
View on StockTwits ↗
$VEEV $NTNX $OOMA $A $NVDA AFTER-HOURS MOVERS: Currently Higher After Earnings: - Okta (OKTA) up 20.5% - Salesforce (CRM) up 13.0% - Lantronix (LTRX) up 13.8% - Phibro Animal Health Corporation (PAHC) up 8.5% - CrowdStrike Holdings (CRWD) up 10.0% - Veeva Systems (VEEV) up 9.0% - Nutanix (NTNX) up 6.3% - Ooma, Inc. (OOMA) up 4.3% - Agilent Technologies (A) up 3.2% - NVIDIA (NVDA) up 4.3% - Everpure, Inc. (P) up 3.1% Currently Also Higher: - Tenable Holdings (TENB) up 7.4% after admission into S&P SmallCap 600 index - Funko (FNKO) up 6.3% after insider buy Currently Lower After Earnings: - HP Inc. (HPQ) down 9.1% - Urban Outfitters, Inc. (URBN) down 2.8% - Synopsys (SNPS) down 1.1% Currently Also Lower: - Wendy's Company (WEN) down 13.2% after Reuters report Trian is backing away from bid.
View on StockTwits ↗$A reported 1.62 EPS and 1,878 revenue for Q3. http://www.estimize.com/intro/a?chart=historical&metric_name=eps&utm_content=A&utm_medium=ac
View on StockTwits ↗
https://www.marketbeat.com/earnings/reports/2026-8-26-agilent-technologies-inc-stock/ $A Agilent Technologies Earnings Transcript
View on StockTwits ↗
$A Q3 '26 Earnings Results & Recap • Reported GAAP EPS of $1.62 up 18.25% YoY • Reported revenue of $1.88B up 8.06% YoY • For fiscal year 2026, Agilent expects revenue between $7.49B and $7.51B, non-GAAP operating margin expansion over 130 basis points at midpoint, and non-GAAP EPS of $6.18 to $6.21.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.